Good morning, everyone. I'm delighted to welcome you to our 2025 interim results presentation. With me this morning is Soraya Benchikh, CFO; and Victoria Buxton, Group Head of Investor Relations. I will begin with our transformation highlights and the progress we have made against our 2025 priorities. Soraya will then take you through our financial results in more detail, before I return to talk more about our performance outlook and why we are confident in the pathway ahead. We will then take your questions. With that, I would like to draw your attention to the disclaimers on Slide 2 and 3. Let's begin by looking at the positive transformation momentum we are driving. Starting with some highlights. We have delivered group results slightly ahead of expectations, which Soraya will talk about in more detail. Smokeless now accounts for 18.2% of group revenue, up 70 basis points versus last year. And we added 1.4 million smokeless consumers reaching 30.5 million, mainly driven by our continued success in Modern Oral. Our focus on quality growth, balancing top and bottom line delivery has driven a further improvement in new category contribution margin up 280 basis points to 10.6% at constant rates. We continue to enhance our financial flexibility enabling us to make progress on the leverage and reward shareholders with strong cash returns. Alongside our progressive dividends, we recently increased our 2025 share buyback by GBP 200 million to GBP 1.1 billion. I'm proud that we have delivered what we said we would in the first half against our 2025 priorities as we continue to build a track record of delivery. Our quality growth focus is central to our new categories execution to ensure we roll out new innovations in a target way while continue to improve our contribution margin. Driving value from our combustible business is essential to funding our transformation and the U.S. is a key driver of this. I'm delighted with our return to both revenue and profit growth in the U.S. for the first time since 2022, driven by combustibles and modern oral. We remain focused on our proactive approach to regulatory affairs and continue to advocate for science-led level playing fields with robust enforcement for smokeless alternatives. In the first half, we activated Omni in 13 markets globally, with further launches planned for the second half of the year. Importantly, all of this is executed with a strong focus on cash generation, enabling us to continue to deleverage and reward shareholders with strong cash returns. I'm pleased to report a notable increase in energy and momentum across the group. And I would like to thank all our teams around the world who are driving these encouraging results. And with that, I will hand over to Soraya to take you through our H1 performance in more detail.

Thank you, Tadeu, and good morning, everyone. I'm pleased to share that our results on a constant currency basis came in slightly ahead of expectations. Our reported numbers include some adjusting items such as a GBP 575 million reduction in our Canadian provision following an update of the forecasted market performance and the GBP 900 million gain from the partial sale of our ITC investment. To give you a clear picture of our underlying performance, I'll focus on constant currency adjusted metrics, and you can find more detail on the adjusting items and market share data in the appendix. In H1, we delivered a strong performance ahead of our original guidance at the upper end of our 1% to 2% revenue growth range. Group revenue was up 1.8%. Adjusted gross profit rose by 3% and adjusted profit from operations grew 1.9% with adjusted diluted EPS increasing by 1.7%. With a stronger-than-expected H1, we now anticipate full year revenue at the top end of our 1% to 2% guidance. We maintain our APFO guidance of 1.5% to 2.5%, reflecting increased investment in new categories and the stronger U.S. combustibles comparator in H2. Let's now turn to new categories. Revenue was up 2.4%, driven by an outstanding growth in Modern Oral, which was up over 40% and Heated Products, which rose by more than 3%, this was partly offset by a 13% decline in Vapour mainly due to illicit trade in the U.S. and Canada. We are delivering quality growth with gross margin up 250 basis points and contribution margin up 280 basis points, reaching 10.6%. This reflects our targeted investments in high-value markets, a disciplined approach to ROI and the benefits of scale. And I'm really proud of the progress we've made, and we expect momentum to build in H2 with…

Thank you, Soraya. I would like to outline our confidence in the pathway ahead. The nicotine industry is rapidly transforming and growing as added consumers around the world are increasingly switch to new categories. We have pursued a mood category strategy from the outset which means we are well placed to benefit from these consumer trends, leveraging our world-class insights, innovation ecosystem, brand building and distribution capabilities, we have invested to build a well-established portfolio of global brands across all 3 new categories. In addition, given our global footprint and with a number of our key markets still close to smokeless alternatives, we recognize that we must continue to invest to drive value from combustibles with a well-balanced portfolio of brands across price tiers. Let me now share more detail on our new category launches. Starting with Modern Oral, the fastest-growing new category by far, which is already reaching global scale. Its position on the risk continue was supported by a recent study which demonstrated that smokers who switch completely to oral nicotine products exposed to lower levels of toxicants similar to those who quit. Modern Oral is highly successful in both traditional oral markets and new markets with no existing oral nicotine tradition and it's also highly profitable with a fast payback, as Soraya mentioned. Following our successful launches in Pakistan and South Africa, we continue to see an exciting opportunity for Modern Oral in emerging markets given its adaptability and affordability. Modern Oral is becoming a meaningful contributor to our group delivery as Velo continues to grow from strength to strength. We are clear leaders in AME close to 6x the size of our closest competitor and capturing around 60% of category growth, which highlights the further opportunity ahead. Velo is a premium product over indexing on value…

Thank you Tadeu and Soraya, and good morning, everyone. [Operator Instructions] And I will now hand over to the operator.

And our first question today comes from Simon Hales with Citi.

Two or 3 for me, if possible, please. Tadeu, can you just talk a little bit more about sort of the early performance that you've seen from the glo Hilo launch into Japan. Obviously, you referenced it in your presentation in terms of the recent share gain you're seeing. Qualitatively, what is the feedback you're getting on the ground from those Japanese consumers. How does it vary at all from what you saw in the test market in Serbia? And how should we think about the scale of the rollout into other key markets through the rest of the year? What percentage of your key Heated tobacco markets do you expect to be in by the end of the year? And then secondly, on Modern Oral, clearly, a very strong performance coming through from Velo Plus in the U.S. and you referenced the further share gain that you've seen coming through into July as well. Have you seen any change in momentum for the brand as you exited the quarter and came into July, given that the biggest competitor on the ground is now back on shelf and perhaps being a little bit more aggressive in its point-of-sale promotional activity? And then finally, just really a clarification for Soraya around the Fit2Win program. I think you said that there won't be any upfront costs until 2026 for that program. There's nothing in the second half of the year. Am I right on that?

Okay. Simon, thanks for your questions. In terms of glo Hilo Japan, the feedback has been really positive from consumers. And its portfolio was much more tailor made from the ones that we have launched in Serbia for the Japanese consumers. We have done a lot of work to get to very competitive offers because it's not just about the device. The device is clearly a massive step change from what we have been offering so far into the Japanese market and also anywhere else in the group. But the consumables are also very important. And we do believe that we have a new technology on the consumables that's combined with the device heating mechanism is offering, like I mentioned in my presentation, the closest we can get from smoking a cigarette in HP product. And this being resonating well with consumers. Have to remember that Sendai, we don't have yet the 2-piece device. And yet, we have achieved it in few weeks, 1.5% at a premium level that we have never been able to compete with glo in terms of consumables pricing. So it's quite exciting about that. In terms of rollout for the rest of the year, we will just start because, like I said, September, Japan, and we'll be hitting the highest profit pools in the HP category until December, but it will be just early stage. We will be probably seeing the impact of that throughout 2026. Now in terms of Modern Oral, yes, we are extremely excited with Velo Plus. The brand is keeping its momentum. And when we launch the brand as any new launch in the U.S. We have a price list, we apply some discounts to get consumer trial. We see that once the trial, the level of retention is still being kept at a very, very high level at 70% of retention and we have been reducing the discount since the launch. And despite that, we carry on seeing increasing in market share and the repurchase at the point of sale. So all in all, we are very, very supportive of the future growth of Velo Plus in the U.S. Today, in terms of pricing, if you strip out the leading brand, we are over-indexed to what is left in the market. And in terms of value share based on the trend that we are seeing, we are very close to achieve the #2 position. So -- we are -- and we'll be going back to a positive contribution already in 2025, which is a testament that this is a category with the right product with the right focus and execution, we can have a very short payback. So all in all, very excited about that. So Soraya?

Simon, thank you for the question. Just let me give a little bit of background on Fit2Win. I think over the years, we've been very good at taking out costs from the business. Fit2Win is slightly different. It's really aimed at making the organization future fit. We're basically reviewing a lot of our key work processes in the organization. and embedding digital decision-making basically into our processes. We're doing a full review of indirects. We're also looking at our routes to market to ensure that they are transformed in line with the business transformation that we're going through. So in answer to your question in terms of the cost -- we've already -- we will have some costs in 2025, but this is fully included in our guidance. And the GBP 500 million will be an annualized saving that we will reach at the end of 2028. And yes, we will be looking to reinvest basically to fuel the growth behind our innovations.

Our next question comes from the line of Damian McNeela from Deutsche Numis.

The first question really is on whether you could provide us a little bit more color on the performance of the vape business in the AME region. I think you sort of flagged some challenges in Canada and also the transition that's happening in some of the bigger markets like the U.K. I was just wondering if you could provide some thoughts on what's happening on the ground and your expectations for vape in those markets over the medium term? And then just on the U.S. vape and just some clarification on the 40% reduction in shipments that you've seen. I guess it's very difficult to have any accurate number. But can you provide us with a sense of sort of what that means in terms of when we might expect to see a change on the ground in terms of illicit availability, please?

Okay. Damian look, the performance in vaping in AME has been heavily impacted by Canada. The situation in Canada, Quebec, the largest province and where most of the sales is happening, has introduced regulations banning all flavors and -- but the level of enforcement is basically none. And we see inundation of illegal products on top of that with the big tanks, big disposable brands, which due to top care, we cannot even offer anything similar to that. So as a consequence, we had a strong business. We still performed quite nicely on the tracked channels, but there is a hidden market that is not showing up in the tracked channels that is inundating the market and making it very hard for responsible companies to compete in a level playing field. So actually -- so as a consequence, the headline numbers of AME get impacted. But one thing that is interesting happening in Europe is that the trend moving from mods to closed systems. And as you imagine, when you buy mods, you're selling a device, so the NTO per unit is higher when you are selling pods in the closed system. So this will translate an impact in the first moment in the top line of the business. On the other hand, this transition actually is positive for BAT in the long run. You take U.K. for example, we have an overall share just over 10% of the vapour business, including mods. And when you zoom in into the closed system, we have a 33% share. So as this transition consolidates and you know that U.K. has just banned mods and the expectation is that we're going to see more and more closed system replacing mods over time, we should be seeing a return to growth in those markets.…

Our next question comes from the line of Rey Wium with Anchor Stockbrokers.

If I can just start off with the U.S. on the combustible side, it's quite heartening to see that the volume decline has sort of now eased to 7.6%. I just want to know whether -- I mean, what is your sort of indication for the remainder of the year? Is there a chance of this rate of decline to ease further? Or is that pretty much where we are going to stabilize? The other question that I have is just on -- I mean, a very strong performance from Velo Plus in the U.S. Now I just want to know, obviously, you are still waiting approval for, I guess, Velo 2, if you can give us any update on that? And given that Velo Plus is already doing so well, I mean, what are you thinking around Velo 2 when that becomes available? And my last question is just a clarification because honestly, I'm a bit confused in terms of your adjusted EPS number. You show it as 162p, but I also see a number that I can't find anywhere in the release, which is the 155.5p which exclude or make the adjustment for Canada, including currency. So I mean, maybe if you could just help us understand what is the real number that you are looking at and what you want us to focus on? Because I mean, the adjusted EPS on that basis is actually down 2.4% and not up. So that will be very helpful just to get some understanding of how we need to think of this way.

Thank you, Rey, for the question. Soraya will cover the point on the adjusted EPS. In terms of volume, industry-wise, we are seeing a slightly improvement compared with the previous year. It's not meaningful. Previous year at this point in time was overall 8.5% decline. This year, it's more on the 8%. I don't think that we'll be seeing a meaningful variance to that until the end of the year. There are -- the consumers are still very stretched. The level of confidence is still low. But obviously, this has been offset partially by the fact of gas price has been reduced. And we know that there is a correlation, inverse correlation between gas price and sales of cigarettes in the U.S., which has been supportive of volumes more recently. And the other big question mark is in terms of how much more enforcement in the illegal vapour disposable products they can do in the U.S. because we also know that some of the weakness that we see in the combustible business are related with the availability of these products in the market. And obviously, if you expect some enforcement, at least the switch out from -- out of combustible toward these products will probably be reduced. In terms of Reynolds, we are very pleased with our performance. It shows that all the commercial plans that we put in place in the last 2 years is resonating with a strong performance on the ground. You can see that by the market share increase, the value share increase. Our price/mix has been very robust. Obviously, we have taken some decisions, mainly pricing related in 2023, 2024 that makes this half year a bit more softer comparator. That's why we call the attention that the second half will be a bit more…

Okay. On the EPS, basically, you're looking at 162.1p, which is on the constant basis. The 155.5p that you see is on current basis. There is an adjusting item, which is our Canadian adjustment, but Victoria and her team are happy to provide you with a full reconciliation. But the number you should be looking at is 162.1p.

Our next question comes from the line of Gaurav Jain with Barclays.

Three questions from me. So first is on your U.S. cigarette pricing, which was almost 12% ahead of your big competitor, and there was clearly a lot of discussion around double drawback in the U.S. market and in the press releases or all these newspaper articles, Reynolds was mentioned a lot. So could you talk about how double drawback is impacting the U.S. business? How much it has changed on a Y-o-Y basis in terms of contribution to your portfolio? So that's my question number one. And question number two is on your overall e-cigarette strategy, it seems you have exited a few markets, especially in APMEA, like Malaysia, etc, called out. So is like something bigger happening in your overall global e-cigarette sort of portfolio, the way you think about it? And then the last question I have is on your Velo Plus. So amazing growth in the U.S., 1.1 billion pouches in 1H. And if we just extrapolate these market share trends, what you are highlighting and what we see in the scanner data, you could be doing like 6x this volume next year, assuming the market keeps growing and you get your fair share. So do you have that kind of capacity? Or will you run into capacity shortages at some point of time?

Okay. So let me start with the drawback. This is a long-standing legal framework to incentivize manufacturing in the U.S. and generate employment. And that's exactly what Reynolds is doing. And so there is a positive impact on the top line coming from this legal framework. And -- but we would be growing anyway independent of the duty drawback. So because there are 3 major drivers behind that. The first one is the more important one is the performance itself. It's the fact that we are growing market share, value share, our price mix is very robust. The fact that we have outperformed the market in terms of volume. If you see the overall industry, like I said, it is more in the 8% to 8.5% decline. We declined less than that. So all this combined, which I call performance is better. And this is the major driver. We also, given what I said more recently in the previous question, we are lapping a more softer comparator because we took some decisions in 2023, 2024 that resulted in some inventory moves, and this also contributes to the very high growth rates that you saw on the combustible level. And finally, we have the drawback that is Reynolds at the back of that balancing out all the structural decline that we have in volumes in the U.S., compensating that through more exports from the U.S. to other markets, generate more employment and more importantly, buying more leaf as well that is supportive of the farmers in the U.S. So that's about the first question. I'm going to skip to the Velo Plus because I need to -- you have to understand better in the second. But the Velo Plus question is all the shares that we are referring to are consumer offtake shares, not shipment shares. So you are right, we are growing fast. And -- because we need to remember that we came from a very small position back end of last year. We barely have something like 6%, 7% of the market. Like I said, our latest number in July is already in the 17% mark. And as I said, when we launched Velo Plus, the fact that we have been so entrenched in this category outside the U.S. allow us to migrate machinery and shortcut the leading time to produce those machineries. So we are very well equipped to the pace of growth that we are seeing in Velo Plus. So we are not expecting any type of difficulty in that sense in the U.S. And the second question is...

Let me try and help a little bit, Gaurav, with the second question. I think you're referring, if I understood correctly, about some of the APMEA resource allocation decisions that we took. It's basically what we've had to do is prioritize given that we're rolling out innovations in all 3 categories. And we have a lot of innovations this year with Velo Plus in the U.S. Velo that continues globally, Vuse Ultra and glo, glo Hilo, which requires a lot of investment. So we've made some purely resource allocation prioritization basically to fund the investments in the largest profit pools. That's what it is. It's not really detracting from these markets. It's just a question of focusing our resources so we can fuel growth across all our innovations.

And part of that is eventually moving out of -- so I think that you were referring to Malaysia vapour. Yes, we had to move out of Malaysia vapour because it's another market that lost completely the possibility of enforcement. So -- and when there is no enforcement, it's very hard to compete. So if you don't have a level playing field and then you align to that, they need to be smart in the way we deploy our resource, and we will make some decisions if that's the case. We try to engage with the government as soon as we can to address the regulatory environment. If we are not able to do, we have to make our calls and Malaysia vapour is one of those.

Our next question comes from Faham Baig with UBS.

A couple from me, if I may. Firstly, you have now raised top line guidance twice in the past 2 months, but the EBIT outlook continues to be reiterated. Can you dive a bit deeper in where the incremental investments are being spent, which you did not budget for at the start of the year? And how you expect these investments to pay back in 2026? And the second question, just can you remind us where we are on ITC hotels? I know you've given your view on this asset previously. But where are we in the process of divesting that stake, please?

Thank you for that, Faham. Firstly, I think let's say, we're very, very pleased with the H1 performance. But I think let me take it from the top line and then talk about the EBIT guidance. The top line, if we look at the 1.8% growth, it's important to remember that we're lapping the investment in H1 in the U.S. So if we looked at the 1.8%, it really equates to 1.4% growth. And that means that we are second half weighted. So because we've got quite a lot of innovations rolling out, as we've mentioned in the presentation. I think it's also important to note that the 1.5% to 2.5% guidance in EBIT that we haven't changed, even though we're at the top line of our NTO growth. We have these innovations, and we're funding the rollouts there. It's not that we didn't anticipate it, but we would like to retain the flexibility to increase the funding to further fuel the growth going into 2026. It's also important to bear in mind that we have had some tariff impact. It hasn't been significant, but we have absorbed it into our guidance. But the main reason is really us to preserve the ability to increase our investments behind the innovations. And the innovations, as you know, are the Vuse Ultra rollout, glo Hilo that we're rolling out the second half of this year and obviously, the continued momentum behind Velo Plus in the U.S. and Velo globally. I don't know if you want to add something?

No, I think that is right. I would just say that we are in a position that we have never been in the past. As a company, we have now very, very competitive product in every single category. It's very exciting. We spoke about that in the CMD October last year, all the efforts, all the strategic partners we are leveraging. And we are seeing some of those products now hitting the market. And Soraya just referred to them, and it's a very strong position to be, very pleased with that. But obviously, this requires more discipline in terms of investing, and they will translate in future for future drivers of growth for the company and -- which is supportive of our guidance moving forward in terms of top line and bottom line as well. On the hotels, on the ITC hotels, I have said before, I continue saying that we -- strategically speaking, we don't intend to be shareholders in a hotel chain in India or outside India. But the fact is that there are some bureaucratic steps that needs to go through in terms of the way that our shareholder of -- that dates back to early 1900s. And I said -- gave this explanation before. And sometimes things take longer for us to be able to unlock those shares, get the right approvals in the right forums, in this case, the Central Bank in India in order to be able to transact. And once we are in this position, we'll be thinking about that because this will be supported for us going back to the corridor of 2.5 to 2x by the end of 2026. So we intend to use the proceeds of the hotel to deleverage further the company.

Our final question comes from Andrei Andon with Jefferies.

A couple from me, please. First, in Modern Oral in Europe, you were the beneficiary of the majority of category growth in H1. Could you perhaps tell us more about the actions you've taken to preserve this advantage in Europe given competitor has been increasingly assertive on growth outside the U.S.? And then second, on U.S. Modern Oral, I noticed Velo Plus is already in 135,000 outlets, which I think is ahead of the previous target for fiscal '25. Are there any incremental distribution gains still to come in H2? Or are you happy with the current distribution base?

Okay. Thank you, Andrei, for the question. In terms of Velo Plus, I will start from the second one. We -- in 135,000 outlets, we are in more than -- a bit more than 9% of the value of the category. So we don't really need to go much beyond that. But what we are seeing is there is a lot of retailers that are buying from wholesalers but they want to have the product and not necessarily is being supported directly by us. And probably -- so it wouldn't be a surprise to see this number going further, but it is already what we consider an optimum number. Our focus now is actually to improve awareness of the brand because it's still low, which also demonstrates a further potential for the brand and activate trial because once the consumer tries the product, like I said, the level of retention is very high. And you have to remember that Modern Oral in the U.S. average daily consumption is 3 pouches, whilst in AME as a region is 6 pouches and Sweden, which is a very mature market, is 12 pouches. So there is a lot of potential growth in terms of the category, provided that you give them a satisfying product, which Velo Plus seems to be addressing this right now as we speak. And that's the reason why we consider that the category has a potential to almost double in the next couple of years. In terms of Modern Oral outside the U.S., yes, there is a lot of new competitors coming in, the more established one, but also new ones because, as I said, it's the fastest-growing category, new category is also the one that ticked the box in a number of areas is in terms of risk continue is probably one of the lowest risks involved. It's very close to a nicotine replacement therapy. There is no inhalation. In terms of affordability, you can address the likes of emerging markets, for example, because there is no device involved on that. And in terms of margins, if anything, even higher than cigarettes. So obviously, there is a lot of attraction there. So what we are doing, you just saw one of the charts that I presented in my presentation, I was covering one of the innovations of Velo that we are putting -- launch in the market in the next couple of months. And this is about us keeping the momentum and being able to offer consumers more innovative products around that and also spend behind the brand building. And we have been doing that diligently through a number of years now. And some of the resource allocation decisions that we have spoken about is exactly to support the growth of Velo that is going from strength to strength, okay?

Okay. Well, thank you very much for your questions. I'm afraid that's all we've got time for today. The IR team will answer any outstanding questions that remain on the web. And with that, I'll hand back to Tadeu for closing remarks.

Okay. Thank you all for listening today and for your questions. To close, we are on track for our full year guidance, having delivered H1 results slightly ahead of expectations. And looking to 2026, I'm confident we have the right building blocks in place to deliver our midterm algorithm. We will continue to reward our shareholders through strong cash returns, including our progressive dividend and sustainable share buyback and deliver long-term growth and value creation. Thank you again for joining us.